7 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
#SideEffects #Table ... DecisionAid #Orals #DM2 ... #Diabetes #Endocrinology ... #Pharmacology #
Metformin Pharmacology Summary
Mechanisms of Action:
 • Suppresses gluconeogenesis by the liver
 • Increases insulin-mediated glucose utilization
Metformin Pharmacology ... agent • Does not cause ... #Metformin #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... not definitively cause ... DPP4 #Inhibitors #Pharmacology ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
Receptor Agonists - Pharmacology ... Ozempic), or daily tablet ... not definitively cause ... #Summary #DM2 # ... diabetes #endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Medication Guide Classes ... Diabetes #Mellitus #DM2 ... #Medications #pharmacology ... #comparison #table ... #endocrinology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
kidney), which causes ... SGLT2 #Inhibitors #Pharmacology ... #Medications #DM2 ... #Diabetes #Endocrinology
Pharmaceutical agents other than olmesartan have been reported to cause villous atrophy on occasion and are
been reported to cause ... are listed in Table ... to be the most frequent ... cause of drug-induced ... #Pharmacology #Drugs